Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of combination therapy using THP-00101 Dapagliflozin 10 mg and THP-00102 Telmisartan 80 mg compared to each drug alone in adults with type 2 diabetes mellitus accompanied by essential hypertension. This phase 3, randomized, double-blind, multi-center trial aims to show the superiority of the combination therapy in improving blood sugar control measured by hemoglobin A1c HbA1c and lowering mean sitting systolic blood pressure MSSBP over 12 weeks. Additional evaluations include secondary efficacy and safety of different drug combinations including THP-00103 Telmisartan 40 mg.
Actively Recruiting
Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.
Actively Recruiting
Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are investigating how common asthma and chronic obstructive pulmonary disease COPD are among workers at the Navanakorn Industrial Zone in Thailand. This observational cross-sectional study focuses on Thai workers aged 18 years and older to understand the presence of these lung conditions in this population. Participants will be asked to complete a questionnaire about respiratory symptoms and will undergo pulmonary function testing using spirometry with a bronchodilator test. This test helps evaluate lung function to identify asthma, COPD, and other abnormalities. The study does not involve any treatment but collects diagnostic data at a single point in time. During the study, participants will provide information through questionnaires and undergo lung function tests. Researchers will measure the prevalence of asthma, COPD, and abnormal lung function among the workers. The study aims to provide important data about respiratory health in this industrial workforce. Participation involves completing the assessments and providing consent, with no ongoing treatment or follow-up required beyond the baseline visit.
Actively Recruiting
Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.
Actively Recruiting
Researchers are evaluating different predictive equations used to estimate the best continuous positive airway pressure CPAP settings for patients with obstructive sleep apnea OSA in Thailand. This observational study compares these CPAP predictive equations with the traditional in-laboratory manual titration method to find which equation most accurately predicts the optimal CPAP pressure. The study involves adult participants suspected of having OSA who will undergo detailed sleep assessments. Participants will take part in an in-laboratory sleep study using Type 1 polysomnography performed at the Sleep Center of Thammasat University. During the sleep study, sleep technicians will apply various CPAP predictive equations based on previous reliable research to estimate the ideal CPAP pressure needed to manage OSA. This approach will be compared directly with manual CPAP titration conducted in the lab. Throughout the study, participants will undergo sleep testing and monitoring to evaluate the accuracy of the CPAP pressure predictions. Researchers will measure how well the predictive equations match the optimal pressure determined by manual titration at baseline. Participants will be closely observed during the sleep study to gather data on their sleep patterns and breathing. The total participation time corresponds to the duration of the in-laboratory sleep study session.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of Dexamethasone given before minimally invasive spine fusion surgery MIS-TLIF to reduce postoperative back pain. This study aims to improve surgical outcomes with minimal side effects by comparing Dexamethasone to a placebo. The trial also investigates morphine use, side effects like nausea, infection rates, blood sugar levels, spinal fusion success, and hospital stay duration. Participants receive either an intravenous injection of Dexamethasone or a normal saline placebo before their MIS-TLIF surgery, which involves fusing 1-2 spinal levels using a less invasive technique. The study includes a randomized, quadruple-blind design comparing these two groups to assess the effectiveness and safety of preemptive Dexamethasone. During the study, back pain and medication use are measured at multiple points up to 12 weeks after surgery. Fusion rates are checked at 6 months, and hospital stay length is monitored for a year. Researchers will also track complications and adverse reactions to gather comprehensive data on recovery and safety. The total participation spans from surgery through a year of follow-up assessments.
1-10 of 18
1